Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Tongji Hospital · Huazhong University of Science and Technology · +1 more institution
Abstract
Immune checkpoint inhibitor (ICI) activates host's anti-tumor immune response by blocking negative regulatory immune signals. A series of clinical trials showed that ICI could effectively induce tumor regression in a subset of advanced cancer patients. In clinical practice, a main concerning for choosing ICI is the low response rate. Even though multiple predictive biomarkers such as PD-L1 expression, mismatch-repair deficiency, and status of tumor infiltrating lymphocytes have been adopted for patient selection, frequent resistance to ICI monotherapy has not been completely resolved. However, some recent studies indicated that ICI resistance could be alleviated by combination therapy with anti-angiogenesis…
Citation impact
- FWCI
- 27.97
- Percentile
- 100%
- References
- 105
Authors
6- MYMing YiCorresponding
Tongji Hospital, Huazhong University of Science and Technology
- DJDechao Jiao
First Affiliated Hospital of Zhengzhou University
- SQShuang Qin
Tongji Hospital, Huazhong University of Science and Technology
- QCQian Chu
Tongji Hospital, Huazhong University of Science and Technology
- KWKongming Wu
First Affiliated Hospital of Zhengzhou University, Tongji Hospital, Huazhong University of Science and Technology
Topics & keywords
- Blockade
- Immune checkpoint
- Angiogenesis
- Biology
- Cancer research
- Immune system
- Cancer
- Cancer treatment
- Good health and well-being